Desai RJ, et al. - Given that generic drugs are a critical component of the healthcare system, accounting for approximately 90% of all US prescriptions dispensed, researchers evaluated the comparative effectiveness of generic vs brand-name drugs, while addressing perception bias potential. The comparison between generic and brand-name initiators involved over 1 million matched pairs; alendronate, calcitonin, glipizide, or quinapril did not exhibit any differences in outcome. For amlodipine and amlodipine-benazepril, the investigators observed a lower risk of the composite cardiovascular endpoint with generics vs brand-name products. Findings suggested an association of the use of generics with comparable clinical outcomes to the use of brand-name products. These outcomes could help to promote educational interventions to increase patient and provider trust in the ability of generic medicines to manage chronic diseases.